I haven't been able to find out why.
They will be presenting some data at AACR, but ASCO will be the main event, due to additional data from the RP2 (+/- Opdivo) trial. Last year the data on just nine patients at SITC sent the stock up by around $20-30 (from memory).
Recent REPL News
- Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024 • GlobeNewswire Inc. • 09/15/2024 01:45:00 PM
- Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024 • GlobeNewswire Inc. • 09/09/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 08:05:15 PM
- Stockholders Vote to Elect Madhavan Balachandran to Board of Directors • GlobeNewswire Inc. • 09/05/2024 12:00:00 PM
- Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024 • GlobeNewswire Inc. • 08/22/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 12:00:04 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/15/2024 04:15:12 AM
- Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma • GlobeNewswire Inc. • 08/13/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/08/2024 12:45:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 12:06:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 12:04:11 PM
- Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/08/2024 12:00:00 PM
- Replimune to Present at Two Upcoming Investor Conferences • GlobeNewswire Inc. • 07/30/2024 08:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/19/2024 08:15:39 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/19/2024 08:15:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 12:36:13 PM
- Replimune Announces $100 Million Private Placement Financing • GlobeNewswire Inc. • 06/13/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 12:30:11 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/07/2024 08:51:06 PM
- Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/07/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 01:15:41 PM
- Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma • GlobeNewswire Inc. • 06/06/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 01:27:39 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM